A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC

Exclusion Criteria

• •1. histologically or cytologically confirmed mixed SCLC and NSCLC;
• •2. known sensitising EGFR mutation and/or ALK translocation in patients with non-squamous NSCLC;
• •3. tumor infiltration into the great vessels on imaging;
• •4. active CNS metastases;
• •5. malignancies other than NSCLC within 5 years;
• •6. anticancer therapy within 4 weeks before the start of trial treatment;
• •7. persisting toxicity related to prior therapy of Grade \> 1;
• •8. treatment with systemic immunostimulatory agents within 4 weeks;
• •9. treatment with systemic immunosuppressive agents within 2 weeks;
• •10. autoimmune diseases;
• •11. interstitial lung disease or other lung diseases that is symptomatic or may interfere the management of suspected drug-related pulmonary toxicity;
• •12. clinically significant cardiovascular or cerebrovascular diseases;
• •13. inadequately controlled hypertension;
• •14. history of hemoptysis (≥ 2.5mL of bright red blood per episode) within 1 month;
• •15. venous or arterial thrombosis within 6 months;
• •16. evidence of bleeding diathesis or coagulopathy;
• •17. use of anticoagulants or thrombolytic agents that has not been stable;
• •18. active Tuberculosis infection;
• •19. significant acute or chronic infections within 1 month;
• •20. known history of testing positive test for HIV or known AIDS;
• •21. hepatitis B virus or hepatitis C virus infection;
• •22. allergic to any component of the treatment regimen;
• •23. other conditions that in the opinion of the investigator would make participation in this clinical trial inappropriate.